Business

Mass. Movers

ArQule’s lead drug faces hurdle on dosing

ArQule is focused on developing next-generation, small-molecule cancer therapeutics.

Joanne Rathe/Globe Staff/File 2007

ArQule is focused on developing next-generation, small-molecule cancer therapeutics.

Woburn-based ArQule Inc. and its development partner, Daiichi Sankyo Co., said that they will implement a lower dose of their treatment for hard-to-treat cases of liver cancer, Dow Jones reported. The change was recommended by a Food and Drug Administration panel following increased incidences of low white blood cell counts. The announcement is the latest hurdle for tivantinib, ArQule’s lead product candidate.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.